Abstract
Droxidopa is a prodrug of noradrenaline that is available for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure, including Parkinson’s disease (PD). On the basis of limited but encouraging evidence from case series and small numbers of patients, droxidopa has been available for more than 20 years in Japan. Two recent large randomized placebo-controlled trials confirmed the short-lasting effect of droxidopa as assessed by the Orthostatic Hypotension Questionnaire composite score, light-headedness/dizziness score, and standing blood pressure in patients presenting with nOH; as such, the United States Food and Drug Administration has approved the use of droxidopa. Subsequent integrated post hoc analyses revealed that droxidopa is well-tolerated for the treatment of symptomatic nOH in patients with PD, and as such it might provide valid clinical advantages. With respect to long-term outcomes, a non-interventional prospective study revealed that fewer nOH patients reported having sustained a fall when evaluated after 6 months of droxidopa treatment compared to baseline; improvements in nOH symptoms, functionality, and quality of life were all sustained for 6 months. However, two out of four trials present conflicting results. Further placebo-controlled clinical trials with better objective outcomes will be needed in order to validate the efficacy of droxidopa for nOH in patients with PD.
This is a preview of subscription content, log in via an institution to check access.
References
Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to Droxidopa. Hypertension. 2015;65:101–7.
Birkmayer W, Birkmayer G, Lechner H, Riederer P. DL-3,4-threo-DOPS in Parkinson’s disease: effects on orthostatic hypotension and dizziness. J Neural Transm. 1983;58:305–13.
Elgebaly A, Abdelazeim B, Mattar O, Gadelkarim M, Salah R, Negida A. Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension. Clin Auton Res. 2016;26:171–80.
Espay AJ, LeWitt PA, Kaufmann H. Norepinephrine deficiency in Parkinson’s disease: the case for noradrenergic enhancement. Mov Disord. 2014;29:1710–9.
François C, Shibao CA, Biaggioni I, Duhig AM, McLeod K, Ogbonnaya A, et al. Six-month use of Droxidopa for neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2019;6:235–42.
Goldstein DS, Holmes C, Sewell L, Pechnik S, Kopin IJ. Effects of carbidopa and Entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS. J Clin Pharmacol. 2011;51:66–74.
Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson’s disease (NOH306A). J Parkinsons Dis. 2014;4:57–65.
Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease (nOH306B). Mov Disord. 2015;30:646–54.
Hauser RA, Biaggioni I, Hewitt LA, Vernino S. Integrated analysis of Droxidopa for the treatment of neurogenic orthostatic hypotension in patients with Parkinson disease. Mov Disord Clin Pract. 2018;5:627–34.
Isaacson S, Shill HA, Vernino S, Ziemann A, Rowse GJ. Safety and durability of effect with long-term, open-label droxidopa treatment in patients with symptomatic neurogenic orthostatic hypotension (NOH303). J Parkinsons Dis. 2016;6:751–9.
Kachi T, Iwase S, Mano T, Saito M, Kunimoto M, Sobue I. Effect of L-threo-3,4-dihydroxy-phenylserine on muscle sympathetic nerve activities in Shy-Drager syndrome. Neurology. 1988;38:1091–4.
Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003;108:724–8.
Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83:328–35.
Kaufmann H, Norcliffe-Kaufmann L, Palma J-A. Droxidopa in neurogenic orthostatic hypotension. Expert Rev Cardiovasc Ther. 2015;13:875–91.
Nagatsu T, Kato T, Numata Y, Ikuta K, Sano M. Phenylethanolamine N-methyltransferase and other enzymes of catecholamine metabolism in human brain. Clin Chim Acta. 1977;75:221–32.
Narabayasahi H, Nakanishi T, Yoshida M. Therapeutic effects of L-DOPS in Parkinson’s disease, double-blind comparative study against placebo as control in patients with long-term levodopa therapy.pdf. Clin Eval. 1987;15:423–57.
Narabayashi H, Kondo T, Hayashi A, Suzuki T, Nagatsu T. L-threo-3,4-dihydroxyphenylserine treatment for akinesia and freezing of parkinsonism. Proc Jpn Acad Ser B Phys Biol Sci. 1981;57:351–4.
Palma J-A, Norcliffe-Kaufmann L, Martinez J, Kaufmann H. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension. Neurology. 2018;91:e1539–44.
Suzuki T, Higa S, Sakoda S, Hayashi A, Yamamura Y, Takaba Y, et al. Orthostatic hypotension in familial amyloid polyneuropathy: treatment with DL-threo-3,4-di-hydroxyphenylserine. Neurology. 1981;31:1323–6.
White WB, Hauser RA, Rowse GJ, Ziemann A, Hewitt LA. Cardiovascular safety of Droxidopa in patients with symptomatic neurogenic orthostatic hypotension. Am J Cardiol. 2017;119:1111–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Ito, M., Watanabe, H. (2020). Droxidopa for the Treatment of Parkinson’s Disease. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_228-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56015-1_228-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56015-1
Online ISBN: 978-3-319-56015-1
eBook Packages: Springer Reference MedicineReference Module Medicine